The White House’s direct-to-consumer (DTC) platform, TrumpRx, is steadily expanding its catalogue, with products from GSK and Amgen the latest to join the collection of drugs offered through the program.
Amgen’s Humira biosimilar Amjevita, migraine med Aimovig and cholesterol drug Repatha became available through TrumpRx on Monday. GSK, meanwhile, is offering DTC discounts on several of its Ellipta inhalers and its flu treatment Relenza through the platform.
Amjevita can be purchased by cash-paying patients for $299 per month, an 80% discount to the med’s list price of $1,484. Aimovig and Repatha are discounted by 62% off their respective list prices, according to the website.
GSK’s Anoro Ellipta comes with a 49% DTC discount. Arnuity Ellipta is between 51-54% lower than its list price through the platform, while the cash price for Incruise Ellipta is 55% lower. Relenza’s TrumpRx price is $52.90 per month, a 10% discount to its original price of $59.
The new additions bring the total of medications offered through TrumpRx to 54 drugs.
The DTC portal also features Novo Nordisk’s popular GLP-1 medicines Ozempic and Wegovy, including in Wegovy’s newest pill form, plus inhalers from AstraZeneca, fertility meds from EMD Serono and plenty of other in-demand medicines.
The website was first announced in September as a part of Trump’s broader effort to impose a “most favored nation” (MFN) pricing model for prescription drugs, which seeks to tie U.S. prices to those in other countries. The Trump administration had issued letters to 17 of the world’s largest drugmakers in July detailing steps they “must take” to align the costs of their U.S. medicines with international reference prices, promising harsh consequences if the companies failed to comply.
Pfizer was the first to play ball, inking a drug pricing deal last fall that relented to MFN price points on its Medicaid products and allowing many of its drugs to be sold through TrumpRx. More than a dozen other drugmakers have since followed.
However, the agreements recently caught the ire of several Senate Democrats, who earlier this month sent letters to certain participating companies requesting clarity on “evidence that these deals will benefit American patients and taxpayers in terms of savings to the Medicaid program.”
TrumpRx was initially meant to go live in January, but stumbled into a delay toward the end of that month that may have been related to antitrust concerns around the website, health consultant and principal at Reid Strategic, Brian Reid, told Politico at the time.
Amgen’s Repatha was one of a handful of drugs highlighted by the White House in its MFN fact sheet in December, which touted nine new agreements with top drugmakers and pointed to specific drugs from BMS, Boehringer Ingelheim, Gilead and more that will soon be offered on the DTC portal.
Earlier this month, Amgen pulled Repatha from the Danish market, as Euractiv Advocacy Lab reported, potentially the first case in the country driven by the U.S.’s MFN policy.
“Due to significant changes in the market, the current tender conditions mean that Amgen is no longer able to supply Repatha to Denmark,” a company spokesperson told news outlet Euractiv at the time. “The price offered does not adequately reflect the value of this innovative medicine, making continued supply commercially unsustainable.”
Amgen unveiled its own Repatha discount in October through its AmgenNow program, which sells the medicine at the same $239 TrumpRx price point.